Clinical trials: Gastrointestinal Tract
Refractory Malignant Solid Neoplasm, Osteosarcoma
AOH1996 for the Treatment of Refractory Solid Tumors
This phase I trial studies the side effects and best dose of AOH1996 in treating patients with solid tumors that do not respond to treatment (refractory).
- Conditions
- Refractory Malignant Solid Neoplasm, Osteosarcoma, Leiomyosarcomas, Synovial Sarcomas
- Trial name
- NCT05227326
- Testing
- PCNA Inhibitor AOH1996
- Where
- 3 sites in United States
- Volunteers
- 92 people
- Sponsor
- City of Hope Medical Center
Cholelithiasis, Gall Stone
Bile Composition in Healthy and Gallstones Patients
Determine differences between lithogenic and non-lithogenic bile composition.
- Conditions
- Cholelithiasis, Gall Stone, Gall Bladder Disease
- Trial name
- NCT03981315
- Testing
- Bile test, Blood test, Gall stone study
- Where
- Spain
- Volunteers
- 62 people
- Sponsor
- Hospital Son Espases
Cystic Fibrosis
Glycemic Monitoring in Cystic Fibrosis
Current guidelines on the diagnoses and management of cystic fibrosis (CF) related diabetes recommend treatment for diabetes based on diagnostic criteria derived from adults with type 2 diabetes.
- Trial name
- GEM (NCT02211235)
- Where
- United States
- Volunteers
- 146 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Mesothelioma, Pancreatic Cancer
A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers
This research is being conducted to determine the biodistribution of radiolabeled amatuximab in tumor and non-tumor tissues in subjects with mesothelin over expressing cancer including mesothelioma, pancreatic, ovarian or non…
- Conditions
- Mesothelioma, Pancreatic Cancer, Ovarian Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT01521325
- Testing
- Amatuximab
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Morphotek
Depressive Symptoms
Feasibility and Effects of a Blended Baduanjin Exercise and Green Tea Consumption Program on Depressive Symptoms, Gut Microbiota and Quality of Life in Older Adults
Depression is a common mental health issue in older adults, often manifesting as insomnia, low mood, vague somatic complaints, cognitive decline, and recurrent thoughts of death or suicide.
- Trial name
- NCT07687940
- Testing
- blended Baduanjin and Green Tea consumption program, Non-treatment control
- Where
- Hong Kong
- Volunteers
- 48 people
- Sponsor
- Hong Kong Baptist University
Ovarian Cancer, Breast Cancer
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
This research is designed to determine if experimental treatment with PARP inhibitor, AZD5305, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced solid…
- Conditions
- Ovarian Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer
- Trial name
- PETRA (NCT04644068)
- Testing
- AZD5305, Paclitaxel, Carboplatin
- Where
- 68 sites in United States, Australia and 12 more
- Volunteers
- 702 people
- Sponsor
- AstraZeneca
Cholecystolithiasis
Optimal Multimodal Analgesia in Laparoscopic Cholecystectomy
To test the current standard of care (SOC) treatment for laparoscopic cholecystectomy with a group receiving SOC + additional perioperative analgesics in terms of postoperative abilities, PONV, pain and discharge time from the…
- Trial name
- NCT00209885
- Testing
- Gabapentin, S-ketamine, Lidocaine
- Where
- Denmark
- Volunteers
- 60 people
- Sponsor
- Hvidovre University Hospital
Biliary Tract Cancer (BTC), Colorectal Cancer (CRC)
A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors
The purpose of this open-label nonrandomized Phase 1/2 study is to evaluate INCB001158 in combination with chemotherapy in participants with advanced/metastatic solid tumors.
- Conditions
- Biliary Tract Cancer (BTC), Colorectal Cancer (CRC), Endometrial Cancer, Gastroesophageal Cancer (GC)
- Trial name
- NCT03314935
- Testing
- INCB001158, Oxaliplatin, Leucovorin
- Where
- 10 sites in United States, Belgium and 1 more
- Volunteers
- 149 people
- Sponsor
- Incyte Corporation
Postoperative Ileus
Effect of TU-100 on Gastrointestinal and Colonic Transit in Humans
The purpose of this study is to compare the dose related effects of orally administered TU-100, a botanical agent that modulates gastrointestinal nerves, on gastrointestinal motility and colonic transit of solids.
- Trial name
- NCT00871325
- Testing
- Daikenchuto (TU-100)
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Tsumura USA
Pancreatic Cancer
Immunotherapy Combined With Radiation and Influenza Vaccine for Pancreatic Cancer.
Pancreatic cancer (PC) remains a dreadful disease due to its often advanced stage at diagnosis and poor sensitivity to chemotherapy. Progression after 1.
- Trial name
- INFLUENCE (NCT05116917)
- Testing
- Nivolumab, Ipilimumab, Influenza vaccine
- Where
- Denmark
- Volunteers
- 19 people
- Sponsor
- Herlev Hospital
Neurogenic Dysphonia, Neurogenic Dysphagia
Neurogenic Dysphonia/Dysphagia Registry
The Neurogenic Dysphonia/Dysphagia Registry is designed to be purely observational (i.e. non-interventional, exploratory). Patient data collected from the registry is expected to be consistent with any information which can be…
- Trial name
- StrongVoice (NCT02493491)
- Where
- 12 sites in United States
- Volunteers
- 146 people
- Sponsor
- Merz North America, Inc.
Microbial Colonization
Rewilding the Human Gut: Reintroduction of the Species Limosilactobacillus Reuteri
The large intestine is home to trillions of microbes, known as the gut microbiome, which perform essential functions, such as digesting food and fighting disease.
- Trial name
- NCT03501082
- Testing
- L Reuteri PB-W1 Strain, L. Reuteri DSM20016T Strain, Non-Industrialized-Type Diet
- Where
- Canada
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Alberta
Extraesophageal Symptoms, Cough
Screening for Barrett's Esophagus in Otolaryngology Patients
The purpose of this project is to develop an accurate method to identify patients that suffer from acid reflux, but may not present with classic reflux symptoms (such as heart burn).
- Conditions
- Extraesophageal Symptoms, Cough, Throat Clearing, Hoarseness
- Trial name
- SCE (NCT00695227)
- Testing
- Screening for Barrett's Esophagus
- Where
- United States
- Volunteers
- 295 people, healthy volunteers welcome
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Endocrine Tumor
Registry of Endocrine Tumors (Thyroid, Parathyroid, Adrenal, Endocrine Pancreas, Endocrine Digestive Tube)
This registry aims to collect informations about patients with endocrine tumors (Thyroid, Parathyroid, Adrenal, Endocrine Pancreas, Endocrine Digestive Tube) who undergo endocrine surgical procedures.
- Trial name
- eurocrine (NCT03410394)
- Where
- France
- Volunteers
- 3,000 people
- Sponsor
- Central Hospital, Nancy, France
Oesophageal Cancer, Gastric Cancer
Modulated Mid-frequency Whole-body Electromyostimulation and Nutritional Therapy in Gastrointestinal Cancer Patients
The purpose of this study is to assess the efficacy of modulated mid-frequency whole-body electromyostimulation (WB-EMS) combined with nutritional therapy in patients with gastrointestinal cancer.
- Conditions
- Oesophageal Cancer, Gastric Cancer, Duodenal Cancer, Colorectal Cancer
- Trial name
- MOMENT (NCT06414122)
- Testing
- mid-frequency whole-body electromyostimulation (WB-EMS), conventional exercise training, nutritional therapy
- Where
- Germany
- Volunteers
- 88 people
- Sponsor
- University of Cologne
Ovarian Cancer, Colorectal Cancer
EMD 273066 in Patients With Recurrent EpCAM Positive Ovarian, Prostate, Colorectal or Non-small Cell Lung Cancers When First Given Cyclophosphamide
This study is looking at the safety and tolerability of the experimental biological drug EMD 273066 when given with low dose cyclophosphamide to patients with recurring EpCAM positive ovarian, prostate, colorectal or non-small…
- Conditions
- Ovarian Cancer, Colorectal Cancer, Carcinoma, Non-small-cell Lung, Prostate Cancer
- Trial name
- NCT00132522
- Testing
- EMD 273066
- Where
- 5 sites in United States, Switzerland
- Volunteers
- 45 people
- Sponsor
- EMD Serono
Acne Vulgaris, Acneiform Eruptions
The Effects of Oral Probiotics and Herbal Supplementation on the Gut Microbiome and Sebum Excretion Rate in Non-Cystic Acne
The purpose of this study is to evaluates how probiotics and dietary supplementation with an herbal powder can shift the gut microbiome in those with non-cystic acne vulgaris.
- Conditions
- Acne Vulgaris, Acneiform Eruptions, Skin Diseases, Sebaceous Gland Diseases
- Trial name
- NCT05919810
- Testing
- Probiotic, Oral herbal powder supplement
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Integrative Skin Science and Research
End-Stage Renal Disease, Gut Microbiome Dysbiosis
Gut Microbiome and p-Inulin in Hemodialysis
The Microbiome trial is a non-randomized, open-label, sequential, multi-center study of p-inulin for patients with hemodialysis-dependent end-stage renal disease.
- Trial name
- NCT02572882
- Testing
- p-inulin
- Where
- 4 sites in United States
- Volunteers
- 13 people
- Sponsor
- University of Pennsylvania
Primary Biliary Cholangitis
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid.
The participants in this study will have confirmed PBC with inadequate response or intolerance to Ursodeoxycholic acid (UDCA), which is a medication used in the management and treatment of cholestatic liver disease.
- Trial name
- ELSPIRE (NCT06383403)
- Testing
- Elafibranor
- Where
- 60 sites in United States, Czechia and 8 more
- Volunteers
- 92 people
- Sponsor
- Ipsen
Cystic Fibrosis
Study of GLPG1837 in Subjects With Cystic Fibrosis (G551D Mutation)
32 cystic fibrosis patients with the G551D mutation will be treated for 4 weeks, consisting of three consecutive treatment periods: two 1-week periods followed by one 2-week period, evaluating one dose of GLPG1837 each.
- Trial name
- SAPHIRA1 (NCT02707562)
- Testing
- GLPG1837 dose 1, GLPG1837 dose 2, GLPG1837 dose 3
- Where
- 16 sites in Australia, Czechia and 3 more
- Volunteers
- 26 people
- Sponsor
- Lakefront Biotherapeutics NV
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.